Akademik Veri Yönetim Sistemi
Retina-Vitreus, cilt.26, sa.2, ss.178-182, 2017 (Scopus)
© 2017 Gazi Eye Foundation. All rights reserved.Purpose: To report four cases with migration of Ozurdex implant (Allergan Inc., Irvine, CA, USA) into the anterior chamber and to describe their clinical features. Methods: Clinical charts of four cases were evaluated for indications for injection, type of surgical intervention and clinical findings (best-corrected visual acuity, anterior segment examination especially for corneal edema, optical coherence tomography findings and intraocular pressure. Results: All patients had a lens capsule defect and a history of vitrectomy. The indications for Ozurdex(®) were cystoid macular edema (CME) (two eyes) and pseudophakic macular edema (two eyes). Their migration time changes from one day to four weeks. The implants were eventually removed from the AC in three of these cases. One of them, whose implant was migrated to the AC three times, still has diffuse corneal edema. Conclusion: Removal or repositioning of the Ozurdex implant into the vitreous should be performed immediately because of the risk of endothelial decompensation. Posterior capsule rupture and weak zonules may trigger migration risk of the Ozurdex.